Skip header and navigation

2 records – page 1 of 1.

Nova Scotia Health Authority. QEII. Pharmacy Department. Halifax, NS: Nova Scotia Health Authority , 2018.
Pamphlet Number
0252
Available Online
View Pamphlet
Digoxin is a medication used to treat heart failure and certain types of irregular heartbeats (arrhythmias). Toloxin® is the brand name of digoxin. This pamphlet explains how to take digoxin, drugs and foods to avoid, warnings, possible side effects, and symptoms that you should mention to your doctor, nurse practitioner, or pharmacist.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Pharmacy Department
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2018
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Digoxin
Atrial Fibrillation
Heart Failure
Subjects (LCSH)
Digoxin
Atrial fibrillation
Heart failure
Abstract
Digoxin is a medication used to treat heart failure and certain types of irregular heartbeats (arrhythmias). Toloxin® is the brand name of digoxin. This pamphlet explains how to take digoxin, drugs and foods to avoid, warnings, possible side effects, and symptoms that you should mention to your doctor, nurse practitioner, or pharmacist.
Responsibility
Prepared by: Pharmacy Department
Pamphlet Number
0252
Less detail

Warfarine sodique

https://libcat.nshealth.ca/en/permalink/chpams36661
Nova Scotia Health Authority. Pharmacy Services. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
2063
Available Online
View Pamphlet
Cette brochure fournit des instructions précises aux patients qui prennent de la warfarine et qui sont traités pour au moins un des problèmes médicaux suivants : fibrillation auriculaire ou atriale (rythme cardiaque irrégulier), valvule prothétique (artificielle), thrombose veineuse (caillot de sang dans une veine profonde) ou embolie pulmonaire (artère du poumon bloquée par un caillot de sang), infarctus du myocarde (crise cardiaque) ou autre problème connexe. Des instructions sont également f…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Alternate Title
Coumadin
Warfarin sodium
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
French
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Warfarin
Anticoagulants
Subjects (LCSH)
Warfarin
Anticoagulants (Medicine)
Abstract
Cette brochure fournit des instructions précises aux patients qui prennent de la warfarine et qui sont traités pour au moins un des problèmes médicaux suivants : fibrillation auriculaire ou atriale (rythme cardiaque irrégulier), valvule prothétique (artificielle), thrombose veineuse (caillot de sang dans une veine profonde) ou embolie pulmonaire (artère du poumon bloquée par un caillot de sang), infarctus du myocarde (crise cardiaque) ou autre problème connexe. Des instructions sont également fournies sur la façon de prendre le médicament, les doses manquées, les analyses sanguines RIN (ou INR), les interactions médicamenteuses et alimentaires, les effets secondaires et les mesures de sécurité. Vous y trouverez aussi des numéros où appeler si vous avez des questions.
This is a French translation of the English pamphlet 0373 “Warfarin Sodium". This pamphlet gives specific directions if you are a patient on warfarin and you are undergoing treatment for at least one of the following conditions: atrial fibrillation (irregular heartbeat), prosthetic (artificial) heart valve, venous thrombosis (blood clot in a deep vein) or pulmonary embolism (artery in the lung blocked by a blood clot), myocardial infarction (heart attack), or another related condition. Directions about how to take this medication, missed doses, INR blood tests, drug and food interactions, side effects, and safety precautions are provided. Contact numbers are also given if you have questions.
Responsibility
Prepared by: Pharmacy Services ; Revised by: Hematology Services, QEII
Pamphlet Number
2063
Less detail